VYNE Therapeutics Inc.
VYNE
$0.37
-$0.01-2.06%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.06% | 43.03% | 18.16% | 39.27% | 19.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.06% | 43.03% | 18.16% | 39.27% | 19.41% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -2.06% | 43.03% | 18.16% | 39.27% | 19.41% |
| SG&A Expenses | -13.13% | -8.69% | -1.37% | 5.35% | -1.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.50% | 47.69% | 48.70% | 24.14% | -7.63% |
| Operating Income | -38.12% | -47.75% | -49.14% | -23.97% | 7.96% |
| Income Before Tax | -38.26% | -47.94% | -42.80% | -15.19% | 14.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.27% | -47.95% | -42.82% | -15.14% | 14.72% |
| Earnings from Discontinued Operations | 95.77% | 95.32% | 95.34% | 97.98% | 76.51% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.59% | -45.11% | -40.00% | -5.56% | 18.97% |
| EBIT | -38.12% | -47.75% | -49.14% | -23.97% | 7.96% |
| EBITDA | -126.37% | 5.87% | 56.25% | 77.54% | 60.85% |
| EPS Basic | 64.91% | 81.75% | 86.65% | 91.56% | 76.73% |
| Normalized Basic EPS | 61.31% | 81.18% | 86.33% | 90.80% | 76.48% |
| EPS Diluted | 64.91% | 81.75% | 86.65% | 91.56% | 76.73% |
| Normalized Diluted EPS | 61.31% | 81.18% | 86.33% | 90.80% | 76.48% |
| Average Basic Shares Outstanding | 42.50% | 111.95% | 314.58% | 1,142.83% | 840.37% |
| Average Diluted Shares Outstanding | 42.50% | 111.95% | 314.58% | 1,142.83% | 840.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |